Epidermolysis Bullosa (EB) Therapeutics Market Report

China Epidermolysis Bullosa (EB) Therapeutics Industry Market Research Report 2023-2029

  • POSTDATE：Sep 18, 2023
  • PAGES：141
  • REPORT CODE：GMM1808792
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Epidermolysis Bullosa (EB) is a category of rare genetic disorders involving the skin and skin-like tissues. EB is generally inherited from one or both parents who have been diagnosed with EB or carry as mutated EB gene. Rarely, EB can also occur in an individual due to a new genetic mutation, which might have been absent in either or both parents. People suffering from EB have fragile skin which causes blisters that can lead to wounds which are difficult to heal. Low prevalence, lack of data, and no available medications make EB a non-curable disease. A Severe form of EB can be a cause of cancer. At present EB is categorized into EB simplex, Junctional EB, Dystrophic EB, and Kindler Syndrome.

    This report elaborates on the current development of the Epidermolysis Bullosa (EB) Therapeutics industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Amryt Pharma

    • Fibrocell Science, Inc

    • Birken AG

    • InMed Pharmaceuticals Inc

    • Novartis

    • RegeneRx Biopharmaceuticals, Inc

    • ProQR Therapeutics NV

    • RegeneRx Biopharma

    • Fresenius

    • GlaxoSmithKline Plc

    • Johnson & Johnson

    • InMed Pharmaceuticals Inc

    • Karus Therapeutics Limited

    • TWi Pharmaceuticals, Inc

    By Type:

    • Pharmacological Drugs

    • Pipeline Therapies

    • Epidermolysis Bullosa Care

    • Surgical Treatment

    By Application:

    • Hospital

    • Clinic

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Epidermolysis Bullosa (EB) Therapeutics Market Overview 2018-2029

    • 1.1 China Epidermolysis Bullosa (EB) Therapeutics Industry Development Overview

    • 1.2 China Epidermolysis Bullosa (EB) Therapeutics Industry Development History

    • 1.3 China Epidermolysis Bullosa (EB) Therapeutics Industry Market Size (2018-2029)

    • 1.4 China Epidermolysis Bullosa (EB) Therapeutics Market Analysis by Type from Production Side

      • 1.4.1 China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Pharmacological Drugs (2018-2029)

      • 1.4.2 China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Pipeline Therapies (2018-2029)

      • 1.4.3 China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Epidermolysis Bullosa Care (2018-2029)

      • 1.4.4 China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Surgical Treatment (2018-2029)

    • 1.5 China Epidermolysis Bullosa (EB) Therapeutics Market Analysis by Application from Consumption End

      • 1.5.1 China Epidermolysis Bullosa (EB) Therapeutics Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

      • 1.5.2 China Epidermolysis Bullosa (EB) Therapeutics Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)

    • 1.6 China Epidermolysis Bullosa (EB) Therapeutics Market Analysis by Region

      • 1.6.1 North China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    Chapter 2 China Epidermolysis Bullosa (EB) Therapeutics Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Epidermolysis Bullosa (EB) Therapeutics Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Epidermolysis Bullosa (EB) Therapeutics Market Status and Competition Analysis in 2023

      • 2.2.3 China Epidermolysis Bullosa (EB) Therapeutics Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Epidermolysis Bullosa (EB) Therapeutics Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Epidermolysis Bullosa (EB) Therapeutics Industry Development

    Chapter 3 Epidermolysis Bullosa (EB) TherapeuticsIndustry Chain Analysis

    • 3.1 Epidermolysis Bullosa (EB) Therapeutics Industry Chain

    • 3.2 Epidermolysis Bullosa (EB) Therapeutics Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Epidermolysis Bullosa (EB) Therapeutics Market

    • 3.3 Epidermolysis Bullosa (EB) Therapeutics Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Epidermolysis Bullosa (EB) Therapeutics Market

    Chapter 4 China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 4.1 China Epidermolysis Bullosa (EB) Therapeutics Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Epidermolysis Bullosa (EB) Therapeutics Total Production Volume and Growth Rate from Production Side

    • 4.5 China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate, by Type

      • 4.5.1 China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Pharmacological Drugs

      • 4.5.2 China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Pipeline Therapies

      • 4.5.3 China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Epidermolysis Bullosa Care

      • 4.5.4 China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Surgical Treatment

    Chapter 5 China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Epidermolysis Bullosa (EB) Therapeutics Total Market Size and Growth Rate from Consumption End

    • 5.5 China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate, by Application

      • 5.5.1 China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate of Hospital

      • 5.5.2 China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate of Clinic

    Chapter 6 China Epidermolysis Bullosa (EB) Therapeutics Market, by Region

    • 6.1 China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Production Value, by Region

    • 6.2 China Epidermolysis Bullosa (EB) Therapeutics Sales Volume and Sales Value, by Region

    Chapter 7 North China Epidermolysis Bullosa (EB) Therapeutics Market Analysis

    • 7.1 North China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 7.2 North China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    Chapter 8 Central China Epidermolysis Bullosa (EB) Therapeutics Market Analysis

    • 8.1 Central China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 8.2 Central China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    Chapter 9 South China Epidermolysis Bullosa (EB) Therapeutics Market Analysis

    • 9.1 South China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 9.2 South China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    Chapter 10 East China Epidermolysis Bullosa (EB) Therapeutics Market Analysis

    • 10.1 East China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 10.2 East China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    Chapter 11 Northeast China Epidermolysis Bullosa (EB) Therapeutics Market Analysis

    • 11.1 Northeast China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 11.2 Northeast China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    Chapter 12 Southwest China Epidermolysis Bullosa (EB) Therapeutics Market Analysis

    • 12.1 Southwest China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 12.2 Southwest China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    Chapter 13 Northwest China Epidermolysis Bullosa (EB) Therapeutics Market Analysis

    • 13.1 Northwest China Epidermolysis Bullosa (EB) Therapeutics Market, by Type

    • 13.2 Northwest China Epidermolysis Bullosa (EB) Therapeutics Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Amryt Pharma

        • 14.1.1 Amryt Pharma Company Profile

        • 14.1.2 Amryt Pharma Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Fibrocell Science, Inc

        • 14.2.1 Fibrocell Science, Inc Company Profile

        • 14.2.2 Fibrocell Science, Inc Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Birken AG

        • 14.3.1 Birken AG Company Profile

        • 14.3.2 Birken AG Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 InMed Pharmaceuticals Inc

        • 14.4.1 InMed Pharmaceuticals Inc Company Profile

        • 14.4.2 InMed Pharmaceuticals Inc Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Novartis

        • 14.5.1 Novartis Company Profile

        • 14.5.2 Novartis Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 RegeneRx Biopharmaceuticals, Inc

        • 14.6.1 RegeneRx Biopharmaceuticals, Inc Company Profile

        • 14.6.2 RegeneRx Biopharmaceuticals, Inc Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 ProQR Therapeutics NV

        • 14.7.1 ProQR Therapeutics NV Company Profile

        • 14.7.2 ProQR Therapeutics NV Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 RegeneRx Biopharma

        • 14.8.1 RegeneRx Biopharma Company Profile

        • 14.8.2 RegeneRx Biopharma Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Fresenius

        • 14.9.1 Fresenius Company Profile

        • 14.9.2 Fresenius Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 GlaxoSmithKline Plc

        • 14.10.1 GlaxoSmithKline Plc Company Profile

        • 14.10.2 GlaxoSmithKline Plc Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Johnson & Johnson

        • 14.11.1 Johnson & Johnson Company Profile

        • 14.11.2 Johnson & Johnson Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 InMed Pharmaceuticals Inc

        • 14.12.1 InMed Pharmaceuticals Inc Company Profile

        • 14.12.2 InMed Pharmaceuticals Inc Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 Karus Therapeutics Limited

        • 14.13.1 Karus Therapeutics Limited Company Profile

        • 14.13.2 Karus Therapeutics Limited Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 TWi Pharmaceuticals, Inc

        • 14.14.1 TWi Pharmaceuticals, Inc Company Profile

        • 14.14.2 TWi Pharmaceuticals, Inc Epidermolysis Bullosa (EB) Therapeutics Market Performance

        • 14.14.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Epidermolysis Bullosa (EB) Therapeutics Industry Research Conclusions

    • 15.2 Epidermolysis Bullosa (EB) Therapeutics Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Industry Market Size (2018-2029)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Pharmacological Drugs (2018-2029)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Pipeline Therapies (2018-2029)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Epidermolysis Bullosa Care (2018-2029)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume, Production Value and Growth Rate of Surgical Treatment (2018-2029)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)

    • Figure North China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    • Figure Central China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    • Figure South China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    • Figure East China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate from 2018-2029

    • Figure Epidermolysis Bullosa (EB) Therapeutics Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Market Share by Type in 2018

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Market Share by Type in 2023

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Pharmacological Drugs (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Pipeline Therapies (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Epidermolysis Bullosa Care (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume and Growth Rate of Surgical Treatment (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Market Share by Application in 2018

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Market Share by Application in 2023

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Total Market Size and Growth Rate from Consumption End

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate of Hospital (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Rate of Clinic (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Region (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Region (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Region (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Production Value by Region (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Production Value Share by Region (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Production Value Share by Region (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Region (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Region (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Region (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Sales Value by Region (2018-2023)

    • Table China Epidermolysis Bullosa (EB) Therapeutics Sales Value Share by Region (2018-2023)

    • Figure China Epidermolysis Bullosa (EB) Therapeutics Sales Value Share by Region (2018-2023)

    • Table North China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Type (2018-2023)

    • Table North China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Figure North China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Table North China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Application (2018-2023)

    • Table North China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Figure North China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Table Central China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Type (2018-2023)

    • Table Central China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Figure Central China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Table Central China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Application (2018-2023)

    • Table Central China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Figure Central China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Table South China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Type (2018-2023)

    • Table South China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Figure South China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Table South China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Application (2018-2023)

    • Table South China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Figure South China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Table East China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Type (2018-2023)

    • Table East China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Figure East China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Table East China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Application (2018-2023)

    • Table East China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Figure East China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Table Northeast China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Type (2018-2023)

    • Table Northeast China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Figure Northeast China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Table Northeast China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Application (2018-2023)

    • Table Northeast China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Table Southwest China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Type (2018-2023)

    • Table Southwest China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Figure Southwest China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Table Southwest China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Application (2018-2023)

    • Table Southwest China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Table Northwest China Epidermolysis Bullosa (EB) Therapeutics Production Volume by Type (2018-2023)

    • Table Northwest China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Figure Northwest China Epidermolysis Bullosa (EB) Therapeutics Production Volume Share by Type (2018-2023)

    • Table Northwest China Epidermolysis Bullosa (EB) Therapeutics Sales Volume by Application (2018-2023)

    • Table Northwest China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Epidermolysis Bullosa (EB) Therapeutics Sales Volume Share by Application (2018-2023)

    • Table Amryt Pharma Company Profile

    • Table Amryt Pharma Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table Fibrocell Science, Inc Company Profile

    • Table Fibrocell Science, Inc Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table Birken AG Company Profile

    • Table Birken AG Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table InMed Pharmaceuticals Inc Company Profile

    • Table InMed Pharmaceuticals Inc Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table Novartis Company Profile

    • Table Novartis Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table RegeneRx Biopharmaceuticals, Inc Company Profile

    • Table RegeneRx Biopharmaceuticals, Inc Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table ProQR Therapeutics NV Company Profile

    • Table ProQR Therapeutics NV Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table RegeneRx Biopharma Company Profile

    • Table RegeneRx Biopharma Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table Fresenius Company Profile

    • Table Fresenius Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline Plc Company Profile

    • Table GlaxoSmithKline Plc Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table Johnson & Johnson Company Profile

    • Table Johnson & Johnson Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table InMed Pharmaceuticals Inc Company Profile

    • Table InMed Pharmaceuticals Inc Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table Karus Therapeutics Limited Company Profile

    • Table Karus Therapeutics Limited Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)

    • Table TWi Pharmaceuticals, Inc Company Profile

    • Table TWi Pharmaceuticals, Inc Epidermolysis Bullosa (EB) Therapeutics Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US